74964-14-0

Basic information

• Product Name: Ginsenoside Rg5
• Synonyms: (3beta,12beta)-12-Hydroxydammara-20(22),24-dien-3-yl 2-O-beta-D-glucopyranosyl-beta-D-glucopyranoside;Ginsenoside Rg31
• CAS NO: 74964-14-0
• Molecular Formula: C42H70O12
• Molecular Weight: 767.01
• Mol File: 74964-14-0.mol

Chemical Properties

• Boiling Point: 859.7°C at 760 mmHg
• Flash Point: 473.7°C
• Appearance: /
• Density: 1.28g/cm³
• Vapor Pressure: 1.93E-34mmHg at 25°C
• Refractive Index: 1.591
• PKA: 12.85±0.70(Predicted)
• CAS DataBase Reference: Ginsenoside Rg5(CAS DataBase Reference)
• NIST Chemistry Reference: Ginsenoside Rg5(74964-14-0)
• EPA Substance Registry System: Ginsenoside Rg5(74964-14-0)

Safety Data

• Hazardous Substances Data: 74964-14-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Ginsenoside Rg5 is used as a therapeutic agent for its anti-inflammatory, anti-cancer, and antioxidant properties, contributing to the treatment and prevention of various diseases and conditions.
Used in Neuroprotective Applications:
Ginsenoside Rg5 is used as a neuroprotective agent to improve cognitive function and protect against neurodegenerative diseases, such as Alzheimer's and Parkinson's disease, due to its ability to support brain health and reduce oxidative stress.
Used in Diabetes Management:
Ginsenoside Rg5 is used as a hypoglycemic agent to lower blood sugar levels and reduce the risk of diabetes and its complications, making it a potential supplement for diabetes management.
Used in Cardiovascular Health:
Ginsenoside Rg5 is used as a cardioprotective agent to reduce the risk of cardiovascular disease by promoting healthy blood circulation and reducing inflammation.
Used in Energy-Boosting Supplements:
Ginsenoside Rg5 is used as an energy-boosting ingredient in supplements to enhance physical performance and reduce fatigue, thanks to its anti-fatigue effects.
Used in Stress-Reducing Supplements:
Ginsenoside Rg5 is used as a stress-reducing ingredient in supplements to alleviate stress and promote relaxation, due to its anti-stress properties.

InChI:InChI=1/C42H70O12/c1-20(2)10-9-11-21(3)23-12-14-42(8)30-22(4)16-28-40(5,6)29(13-15-41(28,7)24(30)17-25(45)31(23)42)53-39-37(35(49)33(47)27(19-44)52-39)54-38-36(50)34(48)32(46)26(18-43)51-38/h10-11,22-39,43-50H,9,12-19H2,1-8H3/b21-11+/t22?,23-,24?,25+,26-,27-,28?,29?,30?,31?,32-,33-,34+,35+,36-,37-,38+,39+,41-,42-/m1/s1

Upstream product

• 41753-43-9 Ginsenoside Rb₁ 
• 38243-03-7 20(R)-ginsenoside Rg₃ 
• 126252-51-5 (3β,12β,20R/20S)-12,20-dihydroxydammar-24-en-yl 2-O-β-D-glucopyranosyl-β-D-glucopyranoside 

Relevant articles and documents

The preparation of ginsenoside Rg5, its antitumor activity against breast cancer cells and its targeting of PI3K

Ginsenosides have been reported to possess various pharmacological effects, including anticancer effects. Nevertheless, there are few reports about the antitumor activity and mechanisms of ginsenoside Rg5 against breast cancer cells. In the present study, the major ginsenoside Rb1 was transformed into the rare ginsenoside Rg5 through enzymatic bioconversion and successive acid-assisted high temperature and pressure processing. Ginsenosides Rb1, Rg3, and Rg5 were investigated for their antitumor effects against five human cancer cell lines via the MTT assay. Among them, Rg5 exhibited the greatest cytotoxicity against breast cancer. Moreover, Rg5 remarkably suppressed breast cancer cell proliferation through mitochondria-mediated apoptosis and autophagic cell death. LC3B-GFP/Lysotracker and mRFP-EGFP-LC3B were utilized to show that Rg5 induced autophagosome-lysosome fusion. Western blot assays further illustrated that Rg5 decreased the phosphorylation levels of PI3K, Akt, mTOR, and Bad and suppressed the PI3K/Akt signaling pathway in breast cancer. Moreover, Rg5-induced apoptosis and autophagy could be dramatically strengthened by the PI3K/Akt inhibitor LY294002. Finally, a molecular docking study demonstrated that Rg5 could bind to the active pocket of PI3K. Collectively, our results revealed that Rg5 could be a potential therapeutic agent for breast cancer treatment.

Conversion of ginsenoside RB1 into six types of highly bioactive ginsenoside Rg3 and its derivatives by FeCl3 catalysis

Ginsenoside Rb1 is an important saponin of ginseng(s); however, Rb1, with 3-O- and 20-O-sugar moieties, has low bioavailability. Here, we report the derivatization of ginsenoside Rb1 to completely generate six types of highly bioactive minor ginsenoside R

Blank mixed micelle, and preparation method and applications thereof

The invention discloses blank mixed micelle, and a preparation method and applications thereof. The blank mixed micelle comprises an amphiphilic copolymer and ginsenoside represented by formula I, ishigh in efficiency, is safe, is stable, is high in targeting performance, is excellent in homogeneity, is stable in quality, is convention in preparation technology, can be used for coating one or a plurality of active substances in drugs or cosmetics and health care substances, and is capable of forming mixed micelle containing loaded active substances. Compared with conventional nanometer micelle, the blank mixed micelle possesses following advantages: the mixed micelle loaded with active substances is excellent in drug forming performance, multiple drug resistance, stability, homogeneity, and safety performance, and is small in particle size; and the curative effect of loaded active drugs on drug resistant cells is better.

The chemical and hydroxyl radical scavenging activity changes of ginsenoside-Rb1 by heat processing

The chemical and hydroxyl radical ({radical dot}OH) scavenging activity changes of ginsenoside Rb1 (Rb1) by heat processing were investigated in this study. Rb1 was changed into 20(S)-Rg3, 20(R)-Rg3,